序贯结局在代偿期肝硬化临床试验设计与评估中优于二分类结局
该研究基于202例无食管静脉曲张的代偿期肝硬化患者5年队列,按六等级序贯结局评估疾病进展。模拟临床试验显示,序贯结局可检出二分类或时间-事件分析无法发现的组间差异,且样本量估计较二分类复合终点降低3至4倍。
要点
- 序贯结局可提高代偿期肝硬化临床试验的统计效能。
- 使用序贯结局所需样本量较二分类复合终点降低3至4倍。
- 传统二分类或时间-事件分析可能漏检组间差异。
核心结论
- 在代偿期肝硬化临床试验中,序贯结局较传统二分类结局可能提供更高统计效能,从而所需样本量更小。
研究设计与样本
- 纳入202例无食管静脉曲张的代偿期肝硬化患者(无腹水、消化道出血、肝性脑病或黄疸)的前瞻性起始队列,报告5年结局,病因主要为病毒性和酒精性,无失访。
主要发现
- 60个月时患者按六等级序贯结局分布为:1级129例、2级43例、3级2例、4级7例、5级5例、6级16例。
- 按基线血小板计数150×10^9/L分组模拟临床试验,序贯结局显示组间差异有统计学意义,而二分类逻辑回归、卡方或时间-事件分析未检出。
- 在假设的预防失代偿研究中,使用序贯结局的样本量估计较二分类复合终点降低3至4倍。
关键数值与推荐
- 序贯结局定义为六等级:1级无疾病进展;2级发生静脉曲张;3级仅出血;4级非出血性单次失代偿;5级多于一次失代偿事件;6级死亡。
临床怎么用
- 在代偿期肝硬化临床试验设计与评估中,可考虑采用序贯结局替代二分类复合终点,以提高效能并减少样本量。
局限性
- 研究基于单中心起始队列且样本量有限,序贯结局的普适性需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Prevention of decompensation is a primary therapeutic target in patients with compensated cirrhosis (CC). However, a major problem is the large sample size and long follow-up required to demonstrate a significant treatment effect because of the relatively low baseline risk. For this reason, it has been recently suggested that ordinal outcomes may be used in this area to gain power and reduce sample size. The aim of this study was to assess the applicability of ordinal outcomes in cirrhosis. APPROACH AND RESULTS: An inception cohort of 202 patients with CC (no ascites, gastrointestinal bleeding, encephalopathy, or jaundice) without esophageal varices was included, and 5-year outcome is reported. Etiology was mostly viral and alcoholic, and there were no dropouts. Ordinal outcome was set according to six grades with a previously established prognostic ordinality: grade 1 = no disease progression; grade 2 = development of varices; grade 3 = bleeding alone; grade 4 = nonbleeding single decompensation; grade 5 = more than one decompensating event; and grade 6 = death. At the 60-month time point, patients were distributed in grades 1 through 6 as follows: 129, 43, 2, 7, 5, and 16, respectively. Emulation of a clinical trial performed by dividing patients based on baseline platelet count into two groups (cutoff, 150 × 109 /L) demonstrated a statistically significant outcome difference between groups when using ordinal outcomes not detectable by binary logistic or chi-square or time-to-event analyses. Additionally, using ordinal outcomes in a hypothetical study to prevent decompensation resulted in sample-size estimates 3-to 4-fold lower than using a binary composite endpoint. CONCLUSIONS: Compared to traditional binary outcomes, the use of ordinal outcomes in trials of cirrhosis decompensation may provide more power and thus may require a smaller sample size.
引用
- D'Amico G, Abraldes JG, Rebora P, et al. Ordinal Outcomes Are Superior to Binary Outcomes for Designing and Evaluating Clinical Trials in Compensated Cirrhosis. Hepatology. 2020. PMID: 31837238. doi:10.1002/hep.31070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。